Kaleido Biosciences Stock Is Trading Higher On Positive KB109 Data In COVID-19 Study

Kaleido Biosciences Inc KLDO reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19.

• KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events.
• The treatment reduced healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits by approximately 62% among patients with one or more comorbidity and about 51% overall.
• For patients with one or more comorbidity, KB109 reduced the median time to resolving the 13 overall COVID-19 symptoms from 30 to 21 days.
• The study also demonstrated a significant reduction in recovery time for patients aged 45 and older or with one or more comorbidity who received KB109 plus self-supportive care compared to patients receiving self-supportive care alone.
• KB109 is a novel, orally administered product candidate based on the Company's Microbiome Metabolic Therapy platform.
• Price Action: KLDO shares are up 8.86% at $10.81 in premarket trading on the last check Wednesday.